Botensilimab (AGEN 1181) is a humanized monoclonal antibody that specifically targets cytotoxic T-lymphocyte antigen 4 (CTLA-4). Botensilimab (AGEN 1181) functions as a potent activator of both innate and adaptive immune responses. Botensilimab (AGEN 1181) is under active research for its capacity to enhance antitumor immunity and modulate checkpoint pathways.
Reinheit:
95.00%
CAS Nummer:
[2408310-37-0]
Target-Kategorie:
Immunology/Inflammation related
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten